Extracellular Vesicles Protect the Neonatal Lung from Hyperoxic Injury through the Epigenetic and Transcriptomic Reprogramming of Myeloid Cells
- 15 December 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 204 (12) , 1418-1432
Abstract
Rationale: Mesenchymal stem/stromal cell (MSC)–small extracellular vesicle (MEx) treatment has shown promise in experimental models of neonatal lung injury. The molecular mechanisms by which MEx afford beneficial effects remain incompletely understood. Objectives: To investigate the therapeutic mechanism of action through assessment of MEx biodistribution and impact on immune cell phenotypic heterogeneity. Methods: MEx were isolated from the conditioned medium of human umbilical cord Wharton’s jelly–derived MSCs. Newborn mice were exposed to hyperoxia (HYRX, 75% O2) from birth and returned to room air at Postnatal Day 14 (PN14). Mice received either a bolus intravenous MEx dose at PN4 or bone marrow–derived myeloid cells (BMDMy) pretreated with MEx. Animals were killed at PN4, PN7, PN14, or PN28 to characterize MEx biodistribution or for assessment of pulmonary parameters. The therapeutic role of MEx-educated BMDMy was determined in vitro and in vivo. Measurements and Main Results: MEx therapy ameliorated core histological features of HYRX-induced neonatal lung injury. Biodistribution and mass cytometry studies demonstrated that MEx localize in the lung and interact with myeloid cells. MEx restored the apportion of alveolar macrophages in the HYRX-injured lung and concomitantly suppressed inflammatory cytokine production. In vitro and ex vivo studies revealed that MEx promoted an immunosuppressive BMDMy phenotype. Functional assays demonstrated that the immunosuppressive actions of BMDMy are driven by phenotypically and epigenetically reprogrammed monocytes. Adoptive transfer of MEx-educated BMDMy, but not naive BMDMy, restored alveolar architecture, blunted fibrosis and pulmonary vascular remodeling, and improved exercise capacity. Conclusions: MEx ameliorate hyperoxia-induced neonatal lung injury though epigenetic and phenotypic reprogramming of myeloid cells.Keywords
This publication has 51 references indexed in Scilit:
- Interleukin-1 receptor antagonist prevents murine bronchopulmonary dysplasia induced by perinatal inflammation and hyperoxiaProceedings of the National Academy of Sciences, 2013
- Cell Therapy for Lung Diseases. Report from an NIH–NHLBI Workshop, November 13–14, 2012American Journal of Respiratory and Critical Care Medicine, 2013
- Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary HypertensionCirculation, 2012
- Mesenchymal Stem Cell‐Mediated Reversal of Bronchopulmonary Dysplasia and Associated Pulmonary HypertensionPulmonary Circulation, 2012
- Bone Marrow Stromal Cells Attenuate Lung Injury in a Murine Model of Neonatal Chronic Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Airway Delivery of Mesenchymal Stem Cells Prevents Arrested Alveolar Growth in Neonatal Lung Injury in RatsAmerican Journal of Respiratory and Critical Care Medicine, 2009
- Chronic Lung Disease after Premature BirthNew England Journal of Medicine, 2007
- LUNG VASCULAR DEVELOPMENT: Implications for the Pathogenesis of Bronchopulmonary DysplasiaAnnual Review of Physiology, 2005
- Gadolinium Chloride Inhibits Pulmonary Macrophage Influx and Prevents O2-Induced Pulmonary Hypertension in the Neonatal RatPediatric Research, 2001
- Alveolar Macrophage Status in Bronchopulmonary DysplasiaPediatric Research, 1988